Oncolytics Biotech, Inc. (USA)  

(Public, NASDAQ:ONCY)   Watch this stock  
Find more results for ONCY
0.725
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.40 - 1.69
Open     -
Vol / Avg. 0.00/1.14M
Mkt cap 83.27M
P/E     -
Div/yield     -
EPS -0.17
Shares 114.12M
Beta 2.50
Inst. own 1%
Aug 5, 2015
Q2 2015 Oncolytics Biotech Inc Earnings Release (Estimated) Add to calendar
Jun 18, 2015
Oncolytics Biotech Inc Annual Shareholders Meeting (Estimated) - 4:30PM EDT - Add to calendar
May 7, 2015
Q1 2015 Oncolytics Biotech Inc Earnings Release
Apr 14, 2015
Oncolytics Biotech Inc at Needham Healthcare Conference
Mar 16, 2015
Q4 2014 Oncolytics Biotech Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -85.95% -82.00%
Return on average equity -106.00% -103.35%
Employees 22 -
CDP Score - -

Address

210-1167 Kensington Cres NW
CALGARY, AB T2N 1X7
Canada
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oncolytics Biotech Inc. (Oncolytics) is a Canada-based development-stage company. The Company is focused on the research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. The Company’s clinical trial program has included human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB) and Valens Pharma Ltd.

Officers and directors

Bradley G. Thompson Ph.D. Executive Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Kirk J. Look Chief Financial Officer
Bio & Compensation  - Reuters
Matthew C. Coffey Ph.D. Chief Operating Officer, Director
Bio & Compensation  - Reuters
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Bio & Compensation  - Reuters
Alan J. Tuchman M.D. Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Age: 67
Bio & Compensation  - Reuters
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Bio & Compensation  - Reuters
Robert B. Schultz Lead Independent Director
Bio & Compensation  - Reuters
James F. Dinning Independent Director
Age: 62
Bio & Compensation  - Reuters
Edwin Levy Ph.D. Independent Director
Bio & Compensation  - Reuters
J. Mark Lievonen Independent Director
Bio & Compensation  - Reuters